LianBio Announces Departure of Chief Executive Officer
19 Dezember 2023 - 10:05PM
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to
bringing innovative medicines to patients in China and other major
Asian markets, today announced that Yizhe Wang, Ph.D., Chief
Executive Officer has resigned from LianBio to pursue other
opportunities.
In connection with his departure, the LianBio Board of Directors
has appointed Adam Stone, Chief Investment Officer of Perceptive
Advisors and member of the LianBio Board of Directors as Interim
Chief Executive Officer.
“Under Yizhe’s leadership, LianBio built a comprehensive
cross-border platform for drug development, advanced multiple
programs into pivotal Phase 3 trials, developed a commercial launch
infrastructure designed to maximize patient access to innovative
new medicines, and executed transformative strategic transactions,”
said Konstantin Poukalov, Executive Chairman of the LianBio Board
of Directors. “I thank Yizhe for his many contributions to LianBio
and look forward to partnering with him on his future
endeavors.”
LianBio’s Board of Directors will continue to represent the best
interests of LianBio and its shareholders and evaluate strategic
alternatives for the Company. The Board of Directors expects to
communicate an update on the ongoing strategic review in the first
quarter of 2024.
About LianBioLianBio is a cross-border
biotechnology company on a mission to bring transformative
medicines to patients in China and other Asian markets. Through
partnerships with highly innovative biopharmaceutical companies
around the world, LianBio is advancing a diversified portfolio of
clinically validated product candidates with the potential to drive
new standards of care across oncology, ophthalmology, inflammatory
disease and respiratory indications. LianBio is establishing an
international infrastructure to position the company as a partner
of choice with a platform to provide access to China and other
Asian markets. For additional information, please visit the
company’s website at www.lianbio.com.
For investor inquiries, please
contact:Elizabeth Anderson, VP Communications and Investor
RelationsE: elizabeth.anderson@lianbio.com T: (646) 655-8390
For media inquiries, please contact: Katherine
Smith, Evoke CanaleE: katherine.smith@evokegroup.com T: (619)
849-5378
LianBio (NASDAQ:LIAN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
LianBio (NASDAQ:LIAN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024